This means that passive immunization with tau antibodies is usually a viable therapeutic goal and the CSF standard of p-tau262/356 or with the microtubule binding domain (MTBD) can serve as a valuable biomarker of tau pathology to watch tau therapeutics in medical trials. Bienvenue to Singulart.